iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
| Autor: | Debbie Hinnen, Jodi Strong |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
business.industry Insulin glargine Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Type 2 diabetes Hypoglycemia medicine.disease Feature Articles 03 medical and health sciences Lixisenatide chemistry.chemical_compound 0302 clinical medicine Postprandial chemistry Internal medicine Diabetes mellitus Internal Medicine medicine 030212 general & internal medicine business Adverse effect medicine.drug Glycemic |
| Zdroj: | Diabetes Spectrum : A Publication of the American Diabetes Association |
| ISSN: | 1944-7353 1040-9165 |
| DOI: | 10.2337/ds17-0014 |
| Popis: | Background. Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia, weight gain, or other objections may lead to clinical inertia, whereby therapy is not intensified and patients live with uncontrolled hyperglycemia and increased risk for complications. Initiation of injectable therapy with a glucagon-like peptide (GLP)-1 receptor agonist and/or basal insulin is a recommended option for patients with type 2 diabetes inadequately controlled on one or more oral agents. Purpose. This article reviews clinical evidence and provides information on dosing and administration of iGlarLixi, a titratable fixed-ratio combination of insulin glargine and the GLP-1 receptor agonist lixisenatide that effectively lowers both fasting and postprandial glucose levels. Findings. In phase 3 trials, iGlarLixi provided greater A1C reduction than insulin glargine or lixisenatide alone, without increased hypoglycemia risk compared with insulin glargine. iGlarLixi did not lead to weight gain versus insulin glargine and was associated with a lower frequency of gastrointestinal adverse effects than lixisenatide. iGlarLixi was recently approved by the U.S. Food and Drug Administration to improve glycemic control in adults with type 2 diabetes inadequately controlled on basal insulin ( Conclusion. iGlarLixi offers an effective and well-tolerated treatment option for patients with type 2 diabetes requiring additional glycemic control, with comparable or improved safety outcomes than its separate components. Because of its simple regimen and low rate of adverse effects, iGlarLixi may improve adherence and, consequently, therapeutic outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|